Cardiovascular
The circulatory system is a vast network of organs and vessels that is responsible for the flow of blood, nutrients, oxygen and other gases, and hormones to and from cells. The system consists of three independent systems that work together: the heart (cardiovascular), lungs (pulmonary), and arteries, veins, coronary and portal vessels (systemic). Together, the heart, blood, and blood vessels make up the cardiovascular component of the circulatory system. It includes the pulmonary circulation, a "loop" through the lungs where blood is oxygenated. It also incorporates the systemic circulation, which runs through the rest of the body to provide oxygenated blood.
Because of its vastness and critical nature, the circulatory system is one of the systems of the body most prone to disease. Disorders of this system are the leading cause of death among adults in the majority of countries world-wide, arteriosclerosis being one of the most common diseases. It is characterized by fatty deposits in the arteries that cause the walls to stiffen and thicken the walls, and may result in restricted blood flow and ischemia. This may result in symptoms such as angina and dyspnea, necrosis, and ultimately in heart attack or stroke. Hypertension, another circulatory is disease, causes the heart to work harder and can lead to complications as a heart attack, a stroke, or kidney failure. Abnormal blood lipid levels, that is high total cholesterol, high levels of triglycerides, high levels of low-density lipoprotein or low levels of high-density lipoprotein (HDL) cholesterol all increase the risk of heart disease and stroke, and are of particular interest of modern research. Besides changing food intake habits of patients suffering from cardiovascular diseases, in combination with the stimulation to increase physical exercise, special medication may also modify a patients blood lipid profile and prevent the person from developing life threatening circulatory diseases.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3144 | (+)-Blebbistatin | Negative control of (±)-Blebbistatin as an inhibitor of class II myosins | €90.00 | |
3074 | (-)-Blebbistatin | Selective inhibitor of class II myosins; Active enantiomer of (±)-Blebbistatin | €90.00 | |
1758 | (R)-(+)-BAY K 8644 | Calcium (Ca2+) channel modulator | €115.00 | |
1714 | (R)-(+)-SLV 319 | Inactive enantiomer of SLV 319 | €95.00 | |
1309 | (R)-(-)-BMS 204352 | Potassium channel opener; Less active enantiomer of Axon 1112 | €145.00 | |
3890 | (R)-(-)-PD123319 ditrifluoroacetate (Optically pure) | Opposite enantiomer of PD123319 ditrifluoroacetate | €140.00 | |
2830 | (R)-CE3F4 | Potent inhibitor of EPAC1 | €120.00 | |
1759 | (S)-(-)-BAY K 8644 | Calcium (Ca2+) channel activator (L-type voltage-gated) | €115.00 | |
2718 | (±)-Blebbistatin | Potent and specific inhibitor of class II myosins | €95.00 | |
1308 | (±)-BMS 204352 | Potassium channel opener; racemate of Axon 1112 | Inquire | |
3488 | (±)-CGP-12177A | β1/β2 adrenoceptor antagonist, β3 adrenoceptor agonist | €120.00 | |
1313 | 1-EBIO | K+ channel opener (Ca2+ activated) | €50.00 | |
2603 | 1-Nitrosocyclohexyl acetate | HNO donor | Inquire | |
2989 | 15-LOX-1 inhibitor i472 | Inhibitor of 15-lipoxygenase-1 (15-LOX-1) | €170.00 | |
4229 | 2',5'-Dideoxyadenosine | P-Site inhibitor of adenylate cyclase | Recently added | €90.00 |
2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |
1190 | 2-Chloroadenosine | Adenosine A1 and A2A agonist | €65.00 | |
1666 | A 357300 hydrochloride | MetAP2 inhibitor | €90.00 | |
3631 | ABR-238901 | Potent S100A8/A9 blocker | €170.00 | |
1188 | Adenosine amine congener | Adenosine A1 agonist | €125.00 | |
2275 | AdipoRon | Orally active small-molecule AdipoR agonist | €80.00 | |
2552 | Adjudin | Non-hormonal male contraceptive with anti-proliferative activity | €125.00 | |
4000 | Aficamten | Next-in-class cardiac myosin inhibitor | €160.00 | |
3856 | AHU-377 tris salt | Inhibitor of Neprilysin | Inquire | |
3524 | AKOS-022 | VDAC1 inhibitor | €120.00 | |
3549 | Aloperine | Potent multifunctional anti-tumor agent | €50.00 | |
2062 | Alprostadil | Prostaglandin EP (1-4) receptor antagonist | €125.00 | |
1218 | AM 251 | CB1 antagonist | €95.00 | |
1219 | AM 281 | CB1 antagonist | €95.00 | |
2791 | AM 4113 | CB1 antagonist | €105.00 |